Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

耐受性 医学 瑞舒伐他汀 安慰剂 阿托伐他汀 内科学 胆固醇 胃肠病学 血脂谱 甘油三酯 胆固醇转移蛋白 内分泌学 不利影响 脂蛋白 病理 替代医学
作者
G. Kees Hovingh,John J.P. Kastelein,Sander J. H. van Deventer,Patrick Round,J. Ford,Danish Saleheen,Daniel J. Rader,H. Bryan Brewer,Philip J. Barter
出处
期刊:The Lancet [Elsevier BV]
卷期号:386 (9992): 452-460 被引量:197
标识
DOI:10.1016/s0140-6736(15)60158-1
摘要

Background Dyslipidaemia remains a signifi cant risk factor for cardiovascular disease and additional lipid-modifying treatments are warranted to further decrease the cardiovascular disease burden.We assessed the safety, tolerability and effi cacy of a novel cholesterol esterase transfer protein (CETP) inhibitor TA-8995 in patients with mild dyslipidaemia. MethodsIn this randomised, double-blind, placebo-controlled, parallel-group phase 2 trial, we recruited patients (aged 18-75 years) from 17 sites (hospitals and independent clinical research organisations) in the Netherlands and Denmark with fasting LDL cholesterol levels between 2•5 mmol/L and 4•5 mmol/L, HDL cholesterol levels between 0•8 and 1•8 mmol/L and triglyceride levels below 4•5 mmol/L after washout of lipid-lowering treatments.Patients were randomly allocated (1:1) by a computer-generated randomisation schedule to receive one of the following nine treatments: a once a day dose of 1 mg, 2•5 mg, 5 mg, or 10 mg TA-8995 or matching placebo; 10 mg TA-8995 plus 20 mg atorvastatin; 10 mg TA-8995 plus 10 mg rosuvastatin or 20 mg atorvastatin or 10 mg rosuvastatin alone.We overencapsulated statins to achieve masking.The primary outcome was percentage change in LDL cholesterol and HDL cholesterol from baseline at week 12, analysed by intention to treat.This study is registered with ClinicalTrials.gov, number NCT01970215.Findings Between Aug 15, 2013, and Jan 10, 2014, 364 patients were enrolled.At week 12, LDL cholesterol levels were reduced by 27•4% in patients assigned to the 1 mg dose, 32•7% in patients given the 2•5 mg dose, 45•3% in those given the 5 mg dose, and 45•3% in those given the 10 mg dose (p<0•0001).LDL cholesterol levels were reduced by 68•2% in patients given 10 mg TA-8995 plus atorvastatin, and by 63•3% in patients given rosuvastatin plus 10 mg TA-8995 (p<0•0001).A daily dose of 1 mg TA-8995 increased HDL cholesterol levels by 75•8%, 2•5 mg by 124•3%, 5 mg by 157•1%, and 10 mg dose by 179•0% (p<0•0001).In patients receiving 10 mg TA-8995 and 20 mg atorvastatin HDL cholesterol levels increased by 152•1% and in patients receiving 10 mg TA-8995 and 10 mg rosuvastatin by 157•5%.We recorded no serious adverse events or signs of liver or muscle toxic eff ects.Interpretation TA-8995, a novel CETP inhibitor, is well tolerated and has benefi cial eff ects on lipids and apolipoproteins in patients with mild dyslipidaemia.A cardiovascular disease outcome trial is needed to translate these eff ects into a reduction of cardiovascular disease events.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
asdf完成签到,获得积分10
1秒前
1秒前
吹圆号的小熊猫的应助被zhp采纳,获得10
1秒前
2秒前
小圆圆o的应助被LLLLCDCD采纳,获得10
2秒前
2秒前
杨洋发布了新的文献求助10
3秒前
爆米花的应助被R萍吖采纳,获得10
3秒前
大个的应助被zcy采纳,获得10
3秒前
4秒前
基恩格发布了新的文献求助10
4秒前
kuolong发布了新的文献求助10
6秒前
KK完成签到,获得积分10
7秒前
daomaihu发布了新的文献求助100
7秒前
8秒前
8秒前
周什么园发布了新的文献求助10
9秒前
9秒前
longnight完成签到,获得积分10
10秒前
任性的牛排完成签到,获得积分10
10秒前
Orange的应助被ggyF采纳,获得10
11秒前
11秒前
初景发布了新的文献求助10
11秒前
科研天才完成签到 ,获得积分10
12秒前
碎觉觉发布了新的文献求助10
12秒前
zcy发布了新的文献求助10
12秒前
kkaky发布了新的文献求助10
13秒前
楼十八完成签到,获得积分10
13秒前
周什么园完成签到,获得积分10
13秒前
14秒前
风吹麦浪发布了新的文献求助10
14秒前
猜猜猜完成签到,获得积分10
14秒前
14秒前
Maestro_S的应助被包容映安采纳,获得10
15秒前
西西完成签到,获得积分10
16秒前
FashionBoy的应助被WU_JIABIN采纳,获得10
17秒前
吃猫的鱼发布了新的文献求助10
17秒前
17秒前
桐桐的应助被zcy采纳,获得10
18秒前
窦函发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175305
求助须知:如何正确求助?哪些是违规求助? 9567097
关于积分的说明 21790117
捐赠科研通 7769782
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556149
邀请新用户注册赠送积分活动 2477241